Welichem Filed Quarterly Report for Period Ended November 30, 2007

BURNABY, BC, Jan. 25 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V: WBI), announced today that the Company filed its second quarter financials and MD&A. The net loss for the three month period ended November 30, 2007 was $493,483 (2006 - $831,878) or 1 cent per share (2006 - 2 cents per share). The net loss for the six month period ended November 30, 2007 was $1,086,587 (2006 - $1,698,579) or 2 cent per share (2006 - 3 cents per share). Detailed information is available on SEDAR website (www.sedar.com).

About Welichem Biotech Inc.

Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of autoimmune diseases and cancer.

ON BEHALF OF THE BOARD
York Yingping Guo
President and Chief Executive Officer

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This press release contains forward-looking statements that include our belief as to the potential of our products. Certain risks and uncertainties such as our ability to successfully commercialize the products could cause the Company's actual results to differ materially from those in the forward-looking statements.

For further information

York Yingping Guo, President and Chief Executive Officer, Tel.: (604) 432-1703, Email: yorkguo@welichem.com

Yan Chen, Business Development Manager, Tel.: (604) 432-1703, Email: investors@welichem.com

--------------------------------------------------------------------------------

Source: Welichem Biotech Inc.